SEDICO Pharmaceutical Industries, one of ACDIMA Group's companies, announced on Wednesday that it began trial operations of its first anti-cancer drug manufacturing plant in Egypt. With investments up to 1 billion Egyptian pounds ($32.7 million), SEDICO said in a statement the project is in cooperation with one of the largest makers of cancer drugs in Italy that had already built more than 63 oncology drug manufacturing plants worldwide. The plant is a step towards achieving national and health security in line with the Egyptian government's efforts to localise the pharmaceutical industry, most particularly the manufacturing of those "strategic and vital medicines like the oncology treatment drugs," said Olfat Ghorab, chairperson of ACDIMA. SEDICO Pharmaceutical's anti-cancer drug manufacturing plant includes a control room that includes the latest technologies in tracking and inspecting the manufacturing process 24 hr/day
"This plant is an unprecedented step that can not only help provide abundant quantities of medicines in the local market but also establish Egyptian cadres for the production of advanced drugs in line with Egypt 2030 vision and strategy that aims to develop the health system." Ghorab added. Under Egypt 2030 vision, the country hopes to become localise this strategic industry and turn into a pharma manufacturing and export hub. Ali Ghamrawy, chairman and CEO of SEDICO, said the plant is a strategic project and will be a landmark in the history of medicine. The plant is working through the most up-to-date technologies, Ghamrawy stated, adding that there is a control room that includes the latest technologies in tracking and inspecting the manufacturing process 24 hours a day.
